Clinical Policy: Bronchial Thermoplasty  
Reference Number: CP.MP.110  
Last Review Date: 03/19

See Important Reminder at the end of this policy for important regulatory and legal information.

Description  
This policy describes the medical necessity requirements for bronchial thermoplasty (BT). BT is a bronchoscopic procedure that utilizes radiofrequency ablation to reduce airway smooth muscle cells. It is designed to serve as a therapeutic option to reduce severe bronchoconstriction for severe persistent asthma.

Policy/Criteria  
It is the policy of health plans affiliated with Centene Corporation that bronchial thermoplasty is not medically necessary for severe asthma because its long-term safety and effectiveness has not been proven.

Background  
Asthma is a common inflammatory syndrome caused by chronic, intermittent obstruction of the lower respiratory tract that affects millions of individuals. This process is mediated by several inflammatory cytokines, chemokines, adhesion molecules, and signal transduction cascades. T helper type 2 (TH2) and type 17 (TH17) CD4+, basophils, eosinophils, mast cells, and type 2 innate lymphoid cells are crucial for mediating the asthmatic response.

BT is a bronchoscopic procedure that applies thermal energy to the airway wall and, thereby, reduces the extent of airway smooth muscle cell hypertrophy via radiofrequency ablation. Some studies published on BT have tested its therapeutic potential against severe asthma. However, the literature recently published on BT has been controversial and the studies evaluating the efficacy of BT have not provided consistent results.

A prospective non-randomized study of 16 patients with stable mild to moderate asthma found a significant reduction in airway hyperresponsiveness without a change in FEV1. The Asthma Intervention Research Trial (AIR), a randomized controlled trial that enrolled 112 patients, showed an improvement in asthma symptoms from BT but no reduction in hyperresponsiveness or FEV1. The Research in Severe Asthma Trial (RISA), a small randomized study that enrolled only 32 patients, assessed the safety of BT in patients receiving high doses of steroids. Despite several complications, including hospitalizations, a difference was seen in the BT group versus control. Some critics argue that these studies lack the statistical power and blinded placebo control to demonstrate clear conclusions on the efficacy of BT’s clinical potential.

In 2010, Castro et al. performed a randomized, controlled trial with 288 patients that included a placebo control. This study was called the Asthma Intervention Research Trial 2 (AIR2). AIR2 found a statistically significant improvement in their primary outcome, which was the score from the Asthma Quality of Life Questionnaire (AQLQ). However, these scores fell below a clinically meaningful threshold. There was no difference in peak flow, rescue medication use, or FEV1. Moreover, several investigators have criticized the AIR2 study for failing to meet
secondary outcome measures such as safety, its patient selection, and its true efficacy.\textsuperscript{8,10,11} Thus, this study also remains controversial.

Hayes conducted a review of the available literature on BT, noting that overall the body of evidence is small and of low quality. The findings were that BT may improve quality of life outcomes, however other results including emergency department visits, symptom relief, and medication use were inconsistent across studies. BT was found to not decrease hospitalization following treatment and it actually increased hospitalization during the treatment period. Treatment with BT was associated with a statistically significant increase in complications such as wheezing, chest discomfort, night awakenings, sputum discoloration, and cough. The quality and quantity of evidence was not enough to establish the long-term safety and efficacy of the procedure.\textsuperscript{12}

Lastly, a meta-analysis of the aforementioned randomized, controlled trials by Wu, et al, suggests that while BT significantly improves AQLQ scores, there were more respiratory adverse events and hospitalizations for respiratory adverse events with BT than with medications or with placebo.\textsuperscript{13}

\textit{European Respiratory Society/American Thoracic Society}

A 2014 joint statement by the European Respiratory Society and American Thoracic Society strongly recommends that BT be performed only in adults with severe asthma, in the context of a clinical trial or independent systematic registry. They conclude that the body of evidence is of very low quality, and that long-term benefits and safety are unknown.

\textit{National Institute for Health and Care Excellence (NICE)}

NICE guidance states that current evidence on the safety and efficacy of BT for severe asthma is adequate to support the use of this procedure provided that standard arrangements are in place for clinical governance, consent and audit. BT should only be done by clinicians with training in the procedure and experience in managing severe asthma. Further research should report details of patient selection and long-term safety and efficacy outcomes.

\textit{Global Initiative for Asthma}

The Global Initiative for Asthma recommends BT as a potential option for highly selected adult patients who have uncontrolled asthma despite use of recommended therapeutic regimens and referral to an asthma specialty center. Evidence is limited and long-term effects compared with control patients are unknown.

\textbf{Coding Implications}

This clinical policy references Current Procedural Terminology (CPT\textsuperscript{®}). CPT\textsuperscript{®} is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2019, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.
### CPT® Codes

<table>
<thead>
<tr>
<th>CPT® Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>31660</td>
<td>Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial thermoplasty, 1 lobe</td>
</tr>
<tr>
<td>31661</td>
<td>Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial thermoplasty, 2 or more lobes</td>
</tr>
</tbody>
</table>

### ICD-10-CM Diagnosis Codes

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J45.20-J45.998</td>
<td>Asthma</td>
</tr>
</tbody>
</table>

### Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Policy developed</th>
<th>Date</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>References reviewed and updated.</td>
<td>04/16</td>
<td>05/16</td>
</tr>
<tr>
<td>Background information from ETS/ATS, NICE, and GINA added. References reviewed and updated.</td>
<td>03/18</td>
<td>03/18</td>
</tr>
<tr>
<td>Background information from NICE updated. Specialist reviewed. References reviewed and updated.</td>
<td>03/19</td>
<td>03/19</td>
</tr>
</tbody>
</table>

### References


**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan
CLINICAL POLICY
Bronchial Thermoplasty

retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

Note: For Medicare members, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at http://www.cms.gov for additional information.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.